Linkage between Psychological Factors and Response to Immune Checkpoint Inhibitor Therapy: A Preliminary Study

被引:3
|
作者
Cohen, Miri [1 ]
Shamay, Yosi [2 ]
Czamanski-Cohen, Johanna [3 ]
Shulman, Katerina [4 ,5 ,6 ]
Keren Rosenberg, Shoshana [6 ]
Abu-Amna, Mahmoud [7 ]
Turgeman, Ilit [7 ]
Merkin Livshits, Ludmila [4 ,6 ]
Birenboim, Revital [1 ]
Dines, Monica [3 ]
Bar-Sela, Gil [5 ,7 ]
机构
[1] Univ Haifa, Sch Social Work, IL-3498838 Haifa, Israel
[2] Technion Israel Inst Technol, Biomed Engn, IL-3109601 Haifa, Israel
[3] Univ Haifa, Sch Creat Arts Therapies, Emili Sagol Creat Arts Therapies Res Ctr, IL-3498838 Haifa, Israel
[4] Carmel Hosp, IL-3436212 Haifa, Israel
[5] Technion Israel Inst Technol, Bruce Rappaport Fac Med, IL-3109601 Haifa, Israel
[6] Lin Med Ctr, IL-6688304 Haifa, Israel
[7] Emek Med Ctr, Canc Ctr, IL-1834111 Afula, Israel
关键词
immune checkpoint inhibitor therapy; cancer; health-related quality of life; emotional distress; cytokines; PD-1; CTLA-4; QUALITY-OF-LIFE; HEALTH; INSTRUMENT; CRITERIA; TRIALS;
D O I
10.3390/cells12202471
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Substantial evidence has accumulated showing that psychological distress affects immune regulation, the response to cancer treatment, and survival. The effect of psychological parameters on the effectiveness of immune checkpoint inhibitor (ICI) treatment has not yet been studied. This preliminary study aimed to (a) examine the associations between psychological factors and responses to ICI treatment and (b) assess the associations between psychological factors and blood measures of sPD-1, sCTLA-4, and cytokines that may alter the effect of ICI treatment. The participants were 62 individuals with advanced cancer, aged 18 years or older, who were candidates for ICI treatment as a new line of treatment. The participants answered questionnaires and provided blood samples and medical data prior to the start of ICI treatment and 3 months after. Perceived health status was positively associated with better responses to ICI treatment. In the subsample of participants with biomarkers, worse health-related quality of life was associated with higher IL-6 and sCTLA-4; emotional distress and sleep difficulties were associated with higher sCTLA-4; and better perceived health was associated with lower IL-6 and TNF alpha. sPD-1 was not associated with psychological measures. This preliminary study found for the first time that some psychological measures could be linked to responses to cancer treatment, possibly via pro-inflammatory cytokines and sCTLA-4.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] An Algorithm as a Biomarker for Response to Immune Checkpoint Inhibitor Therapy
    Rimm, David L.
    JAMA ONCOLOGY, 2023, 9 (01) : 60 - 61
  • [2] Prediction of response to Immune Checkpoint Inhibitor Therapy by FDG PET
    Massri, K.
    Dellavedova, L.
    Stoico, R.
    Calcagno, A.
    Maffioli, L.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S443 - S443
  • [3] Nephrotoxicity in immune checkpoint inhibitor therapy: A pharmacovigilance study
    Haeuser, L.
    Marchese, M.
    Cone, E. B.
    Noldus, J.
    Bayliss, G.
    Kilbridge, K. L.
    Trinh, Q-D.
    EUROPEAN UROLOGY, 2021, 79 : S1361 - S1362
  • [4] Nephrotoxicity of immune checkpoint inhibitor therapy: a pharmacovigilance study
    Haeuser, Lorine
    Marchese, Maya
    Cone, Eugene B.
    Noldus, Joachim
    Bayliss, George
    Kilbridge, Kerry Laing
    Quoc-Dien Trinh
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2022, 37 (07) : 1310 - 1316
  • [5] NEPHROTOXICITY IN IMMUNE CHECKPOINT INHIBITOR THERAPY: A PHARMACOVIGILANCE STUDY
    Haeuser, Lorine
    Marchese, Maya
    Cone, Eugene B.
    Noldus, Joachim
    Bayliss, George
    Kilbridge, Kerry Laing
    Quoc-Dien Trinh
    JOURNAL OF UROLOGY, 2021, 206 : E261 - E262
  • [6] Morphology of immune-mediated hepatitis: A comparison between immune checkpoint inhibitor therapy and combined immune checkpoint inhibitor/anti-angiogenic therapy
    Zhang, Qiongyan
    Chen, Lingli
    Guo, Xinxin
    Shen, Licheng
    Huang, Yufeng
    Chen, Yi
    Zhang, Ningping
    Ge, Ningling
    Gao, Hong
    Zhang, Wen
    Hou, Yingyong
    Ji, Yuan
    ANNALS OF DIAGNOSTIC PATHOLOGY, 2024, 68
  • [7] Collaboration Between Rheumatology and Oncology in Immune Checkpoint Inhibitor Therapy
    Kimpel, Donald L.
    Lewis, Janet E.
    Gaughan, Elizabeth
    Grosh, William W.
    Brenin, Christiana
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (26) : 2743 - +
  • [8] Thromboembolism during immune checkpoint inhibitor therapy: frequency and risk factors
    Ide, Takayuki
    Araki, Taisuke
    Koizumi, Tomonobu
    DISCOVER ONCOLOGY, 2024, 15 (01)
  • [9] Immune Checkpoint Inhibitor Therapy Toxicities
    Jim, Heather S. L.
    Knoop, Hans
    Dicker, Adam P.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2021, 326 (01): : 87 - 87
  • [10] The role of the gut microbiome in regulating the response to immune checkpoint inhibitor therapy
    Dean, Nathan J.
    d'Arienzo, Paolo D.
    Ibraheim, Hajir
    Lee, Karla A.
    Olsson-Brown, Anna C.
    Pinato, David J.
    Powell, Nicholas
    BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2024, 72